Prostate Cancer
Selecting the optimal radiation modality in prostate cancer.
September 14, 2023
Targeting hyaluronan-mediated motility receptor (HMMR) enhances response to androgen receptor signalling inhibitors in prostate cancer.
September 14, 2023
Perspectives on prostate cancer: advances and pending challenges for a multidisciplinary oncological approach in South America.
September 14, 2023
The androgen receptor does not directly regulate the transcription of DNA damage response genes.
September 14, 2023
Opposing Roles of SPOP Mutations in Human Prostate and Endometrial Cancers.
September 14, 2023
Racial differences in serum chemokines in prostate cancer patients.
September 14, 2023
Metformin Overcomes the Consequences of NKX3.1 Loss to Suppress Prostate Cancer Progression.
September 14, 2023
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.
September 14, 2023
Fulvestrant increases the susceptibility of enzalutamide-resistant prostate cancer cells to NK-mediated lysis.
September 14, 2023
Evolution of structural rearrangements in prostate cancer intracranial metastases.
September 14, 2023
BOP Preliminary Trial Results Presented at EANM 2023 Conference
September 13, 2023
Evaluation of Industry Payments to US Advanced Practice Clinicians in 2021
September 13, 2023
Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer.
September 13, 2023
Limitations of Prostate Biopsy in Detection of Cribriform and Intraductal Prostate Cancer.
September 13, 2023